Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024, representing a decline of approximately 58.1% [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024, a decrease of about 78.4% [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - For the full year 2025, total operating costs and expenses were $52.3 million, significantly reduced from $180 million in 2024 [23] - The net loss for Q4 2025 was $14.6 million, or $3.61 per share, compared to a net loss of $8.7 million, or $2.15 per share in Q4 2024 [25] - The net loss for the full year 2025 was $58.2 million, or $14.40 per share, down from a net loss of $153.1 million, or $38.26 per share in 2024 [25] - As of December 31, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease that has become castration-resistant [7] - The incidence of grade 3 or greater neutropenia was substantially reduced with the utilization of GCSF prophylaxis in ongoing trials [12] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company is focused on developing FG-3246 and its companion FG-3180 program, with expected interim analysis from the phase 2 monotherapy trial in the second half of 2026 [27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway and invest in U.S. pipeline opportunities [26] - The company remains confident in its positioning to create meaningful therapeutic options for patients and significant value for shareholders [7] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of 7 years of regulatory exclusivity [22] - The company is exploring opportunities to develop roxadustat internally or with a strategic partner [21] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the potential market for CD46 PET imaging agents and how they would fit into the treatment algorithm alongside existing PSMA agents [30][32] - The company anticipates that patients will need to show positive uptake of CD46 PET imaging to be prescribed FG-3246, similar to the requirements for PSMA agents [34] Question: SUV data and patient selection - Management acknowledged the provocative nature of the SUV data and its potential role in enriching patient selection for treatment [30][40] - The phase 2 trial is designed to define CD46 positivity, which may be based on SUV or other metrics [40] Question: Balance of patients in studies and recruitment - Management clarified that the phase 2 monotherapy trial will focus on patients who have progressed on only one prior ARPI, differentiating it from the IST [46] Question: Updates on roxadustat partnering efforts - Management stated that they are evaluating the opportunity to develop roxadustat internally or through collaboration but did not provide specific updates on the partnering process [49] Question: FDA feedback timeline for roxadustat - Management explained that the FDA indicated a feedback timeline of 60-90 days due to the nature of the protocol submission, which is currently being awaited [53]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024 [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024 [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - Total operating costs and expenses for the full year 2025 were $52.3 million, down from $180 million in 2024 [23] - R&D expenses for Q4 2025 were $7.3 million, compared to $6.9 million in Q4 2024 [24] - R&D expenses for the full year 2025 were $23.5 million, down from $95.7 million in 2024 [24] - SG&A expenses for Q4 2025 were $7.3 million, compared to $8.3 million in Q4 2024 [24] - SG&A expenses for the full year 2025 were $27.7 million, down from $49.3 million in 2024 [24] - The net loss from continuing operations for Q4 2025 was $14.6 million, compared to a net loss of $8.7 million in Q4 2024 [25] - The net loss from continuing operations for the full year 2025 was $58.2 million, compared to a net loss of $153.1 million in 2024 [25] - As of December 31, 2025, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [7][8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease [7] - Current treatments for anemia associated with lower-risk MDS are effective in less than 50% of patients, highlighting the need for new therapies [18] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company plans to initiate a phase III trial for roxadustat in the second half of 2026 [21][27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway [26] - The company remains confident in its clinical programs and the potential for FG-3246 and FG-3180 to provide meaningful therapeutic options [7][27] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of seven years of regulatory exclusivity [22] - The company is actively enrolling patients for the FG-3246 phase II trial and expects interim results in the second half of 2026 [15][27] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the positioning of CD46 PET imaging agents in relation to existing PSMA agents and the anticipated commercial opportunity [30][32] Question: SUV data and patient selection - Management addressed the correlation between SUV data and patient selection, noting the need to define CD46 positivity metrics in the phase II trial [30][40] Question: Balance of patients in studies - Management clarified that the phase II monotherapy trial will focus on patients who have progressed on one prior ARPI, differentiating from the IST [46] Question: Updates on roxadustat partnering efforts - Management indicated ongoing evaluations for internal development versus potential collaborations for roxadustat but did not provide specific updates [49] Question: Delay in FDA feedback for roxadustat - Management explained the expected timeline for FDA feedback on the IND submission, indicating a 60-90 day period for response [53][54]

Core Insights - Kyntra Bio reported financial results for Q4 and full year 2025, highlighting a significant decrease in revenue and an increase in net loss compared to the previous year [13][19] - The company is advancing its clinical trials, particularly the Phase 2 monotherapy trial of FG-3246 and the Phase 3 trial protocol for roxadustat, with expectations for interim results and FDA feedback in 2026 [2][5][6] Financial Performance - Total revenue for Q4 2025 was $1.3 million, down from $3.1 million in Q4 2024 [13] - Full year 2025 revenue totaled $6.4 million, a decrease from $29.6 million in 2024 [13] - Net loss for Q4 2025 was $14.6 million, or $3.61 per share, compared to a net loss of $8.7 million, or $2.15 per share, in Q4 2024 [13][19] - For the full year 2025, net loss was $58.2 million, or $14.40 per share, compared to a net loss of $153.1 million, or $38.26 per share, in 2024 [13][19] - As of December 31, 2025, the company had $109.4 million in cash and equivalents, sufficient to fund operations into 2028 [13] Clinical Developments - The Phase 2 monotherapy trial of FG-3246 is actively enrolling, with interim analysis expected in the second half of 2026 [5][6] - Positive results from a combination study of FG-3246 with enzalutamide were presented at ASCO GU 2026, showing a median radiographic progression-free survival of 7.0 months [6] - The pivotal Phase 3 trial protocol for roxadustat has been submitted to the FDA for treating anemia in patients with lower-risk myelodysplastic syndromes [5][6] Upcoming Milestones - Kyntra Bio anticipates feedback from the FDA regarding the Phase 3 trial protocol for roxadustat shortly, with plans to initiate the trial in the second half of 2026 [2][5] - The company is exploring opportunities to develop roxadustat either internally or with a strategic partner [6]

Core Viewpoint - Kyntra Bio announced promising preliminary data on the anti-tumor activity of FG-3246 in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC), with results to be presented at the 2026 ASCO GU symposium [1][2] Study Results - The Phase 1b/2 study showed a composite response rate of 21% in the overall cohort and 40% in patients who had progressed on only one prior androgen receptor pathway inhibitor (ARPI) [3] - Median radiographic progression-free survival (rPFS) was 7.0 months in the overall cohort, with a notable 10.1 months in patients who had only one prior ARPI [3][4] - Higher tumor uptake of FG-3180 indicated a trend towards a higher probability of PSA50 response (p=0.053), suggesting its potential as a biomarker for patient selection [3][4] Safety Profile - The combination therapy of FG-3246 and enzalutamide exhibited a safety profile similar to that observed in previous trials, with neutropenia risk mitigated through G-CSF prophylaxis [4][5] - Common treatment-related adverse events (TRAEs) included fatigue, peripheral neuropathy, anorexia, and dysgeusia, with some patients discontinuing treatment due to cumulative toxicities [5] Future Developments - Kyntra Bio is on track to provide interim analysis results from the Phase 2 monotherapy trial of FG-3246 in the second half of 2026, which will further explore the utility of FG-3180 as a patient selection biomarker [4][6] - FG-3246 is being developed as a first-in-class antibody-drug conjugate targeting CD46, with potential applications in other tumor types beyond mCRPC [7][9]

Core Insights - FibroGen, Inc. is rebranding to Kyntra Bio, focusing on oncology and rare disease assets, with trading under the new Nasdaq symbol "KYNB" starting January 8, 2026 [1][6] Company Transformation - 2025 was a pivotal year for the company, marked by the sale of FibroGen China, repayment of a senior secured term loan, and extending its cash runway into 2028 [2] - The rebranding reflects a sharpened focus on mid- and late-stage assets, particularly FG-3246, a CD46 targeting antibody drug conjugate, and FG-3180, a companion PET imaging agent in a Phase 2 trial for prostate cancer [2][4] Product Development and Clinical Trials - Roxadustat, approved in multiple countries for treating anemia in chronic kidney disease, is being evaluated for a Phase 3 trial in the U.S. for lower-risk myelodysplastic syndromes [4] - FG-3246 is in Phase 2 development for metastatic castration-resistant prostate cancer, with interim results from the ongoing monotherapy trial expected in the second half of 2026 [7] - The company has received Orphan Drug Designation from the FDA for myelodysplastic syndromes and submitted a pivotal Phase 3 clinical trial protocol for roxadustat [7] Corporate Strategy - The company is refreshing its corporate website to align with its new strategic direction [3] - Kyntra Bio aims to create a significant impact for patients and shareholders through its focused approach on novel therapies [2][6]

Core Insights - FibroGen has completed the sale of its China operations to AstraZeneca for approximately $220 million, simplifying its capital structure and extending its cash runway into 2028 [2][5][6] - The company has initiated a Phase 2 monotherapy trial for FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer, with interim results expected in the second half of 2026 [2][5][6] - FibroGen is on track to submit the Phase 3 protocol for roxadustat for the treatment of anemia in lower-risk myelodysplastic syndromes in the fourth quarter of 2025 [2][7] Recent Developments - The sale of FibroGen China included $85 million in enterprise value and approximately $135 million in net cash held in China [5][6] - The company has successfully repaid its term loan to Morgan Stanley Tactical Value, further simplifying its capital structure [6] - FibroGen maintains rights to roxadustat in the U.S. and other markets outside of China, South Korea, and those licensed to Astellas [6] Financial Performance - Total revenue for Q3 2025 was $1.1 million, compared to $0.1 million in Q3 2024 [15] - The net loss from continuing operations for Q3 2025 was $13.1 million, or $3.25 loss per share, a significant improvement from a loss of $48.3 million, or $12.01 loss per share, in the same quarter last year [15] - As of September 30, 2025, the company reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, sufficient to fund operations into 2028 [15] Upcoming Milestones - Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide are expected to be presented at a medical conference in Q1 2026 [5][6] - The interim analysis for the Phase 2 monotherapy trial of FG-3246 is anticipated in the second half of 2026 [2][6] - The final protocol submission for the pivotal Phase 3 trial of roxadustat is expected in Q4 2025 [7]

Core Viewpoint - FibroGen, Inc. has successfully completed the sale of its China subsidiary to AstraZeneca for approximately $220 million, significantly enhancing its financial position and extending its cash runway into 2028 [1][2][7] Financial Impact - The total consideration for the sale includes $85 million in enterprise value and about $135 million in net cash held in China, marking a $60 million increase from initial guidance [1][7] - Following the sale, FibroGen repaid its term loan facility to Morgan Stanley Tactical Value for approximately $81 million, simplifying its capital structure [2][7] Clinical Development Plans - The company is on track to initiate the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in the third quarter of 2025 [2][4][7] - FibroGen intends to submit the Phase 3 protocol for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the fourth quarter of 2025, following a positive meeting with the U.S. FDA [3][4] Product Rights and Development - FibroGen retains rights to roxadustat in the U.S. and all markets not licensed to Astellas, excluding China and South Korea [3] - The company continues to advance the clinical development of FG-3246 and its companion diagnostic FG-3180 [4][5]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $1.3 million, an increase from $1 million in Q2 2024 [28] - The company raised its full-year revenue guidance to between $6 million and $8 million for 2025 [28] - Total operating costs and expenses decreased to $13.4 million in 2025 from $47.4 million in 2024, a reduction of 72% year over year [29] - R&D expenses were $5.9 million in 2025, down from $32.4 million in 2024, representing an 82% decrease [29] - SG&A expenses decreased to $7.1 million in 2025 from $14.9 million in 2024, a 53% reduction [29] - The net loss from continuing operations was $13.7 million or $3.38 per share in 2025, compared to a net loss of $47.1 million or $11.79 per share in 2024 [29] - Cash and cash equivalents totaled $142.1 million, including balances in China, with the company being cash flow positive in Q2 2025 [30] Business Line Data and Key Metrics Changes - The sale of FibroGen China to AstraZeneca is expected to provide total consideration of approximately $210 million, an increase of $50 million from initial guidance [5][26] - The transaction is anticipated to extend the company's cash runway into 2028 [5][27] Market Data and Key Metrics Changes - The total addressable market for FG3246 in the U.S. is estimated to exceed $5 billion annually, targeting metastatic castration-resistant prostate cancer [9] - The company is focused on addressing the unmet need in late-stage prostate cancer, with a five-year survival rate of approximately 30% for patients [8] Company Strategy and Development Direction - The company is prioritizing the sale of FibroGen China, advancing FG3246 and FG3180 in metastatic castration-resistant prostate cancer, and refining the pathway for roxadustat in treating anemia due to lower-risk myelodysplastic syndromes [4][5] - FG3246 is positioned as a potential first-in-class antibody-drug conjugate targeting CD46, with a companion PET imaging agent FG3180 [10][11] - The company aims to finalize the Phase III trial design for roxadustat and submit the protocol in 2025 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's refined focus and simplified capital structure, which are expected to create value for patients and shareholders [8] - The company anticipates multiple near-term catalysts, including the initiation of the Phase II monotherapy study for FG3246 and reporting top-line results from the Phase II IST for FG3246 in combination with enzalutamide [33] Other Important Information - The company recorded a significant decrease in operating costs, reflecting a strategic shift and operational efficiency [29] - The FDA provided positive feedback regarding the pivotal Phase III trial for roxadustat, aligning on key design elements [23] Q&A Session Summary Question: Insights on FG3246 and Phase III design considerations - Management acknowledged the evolving nature of the field and the potential inclusion of docetaxel in the control arm for Phase III trials, emphasizing the need for further discussions [36][39] Question: Updates on roxadustat's exclusivity and trial design - Management confirmed a minimum of seven years of exclusivity with orphan drug designation for roxadustat and stated that the Phase III trial will be placebo-controlled [44][48] Question: Feedback from the physician community on FG3246 Phase I data - Management reported positive feedback from clinical sites regarding FG3246, highlighting its potential in the unmet need space for metastatic castration-resistant prostate cancer [56][58]

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $2.7 million, a significant decrease from $25.4 million in the same period in 2024 [28] - Total operating costs and expenses for Q1 2025 were $17.7 million, down from $74.5 million in Q1 2024, representing a 76% year-over-year decrease [29] - The net loss from continuing operations for Q1 2025 was $16.8 million, or $0.16 per share, compared to a net loss of $49 million, or $0.49 per share, in Q1 2024 [29] Business Line Data and Key Metrics Changes - R&D expenses for Q1 2025 were $9.2 million, down from $36.5 million in Q1 2024, a decrease of 75% year-over-year [29] - SG&A expenses for Q1 2025 were $8.1 million, compared to $16.7 million in Q1 2024, a decrease of 51% year-over-year [29] Market Data and Key Metrics Changes - The total addressable market for FG3246 in metastatic castration-resistant prostate cancer (mCRPC) is estimated to be over $5 billion in annual sales [10] - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with 65,000 being drug-treatable patients in the metastatic castration-resistant stage [9] Company Strategy and Development Direction - The company is focused on advancing its U.S. pipeline opportunities, particularly FG3246 and FG3180, while divesting FibroGen China to simplify operations and extend cash runway [5][6] - The sale of FibroGen China to AstraZeneca is expected to close in Q3 2025, with total consideration now estimated at approximately $185 million, an increase from the initial guidance [5][6][27] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the refined focus and multiple near-term catalysts across clinical programs, positioning the company well for shareholder value creation [9] - The company anticipates FDA feedback on roxadustat's development for anemia associated with lower-risk myelodysplastic syndromes (MDS) in Q3 2025 [8] Other Important Information - The company reported cash flow positive results in Q1 2025, generating $7.3 million in cash flow on a consolidated basis [30] - Upon closing the China transaction, the company plans to pay off its senior secured term loan, resulting in a cash outflow of approximately $80 million [30] Q&A Session Summary Question: Regarding clinical development on FG3246 and market dynamics after Pluvicto approval - Management confirmed that Pluvicto experienced patients will be allowed in the Phase II monotherapy trial to mitigate enrollment challenges [39][40] Question: Comments on recent FDA correspondence regarding roxadustat - Management reported favorable interactions with the FDA, including timely responses for IND filings and Type C meeting requests [41][42][43] Question: Feasibility studies in colorectal cancer given cash infusion from AstraZeneca - Management indicated that they will hold off on colorectal cancer studies for now, focusing on initiating the Phase II monotherapy trial [44][45] Question: Rate limiting steps ahead of the upcoming Phase II monotherapy study - The close of the China transaction is the primary rate limiter for starting the Phase II monotherapy trial [50] Question: Evolving commercial opportunity for FG3180 - Management highlighted the importance of the Phase II trial in assessing the commercial potential of FG3180 as a diagnostic tool [52][54]

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $2.7 million, a significant decrease from $25.4 million in Q1 2024 [27] - Total operating costs and expenses for Q1 2025 were $17.7 million, down 76% year-over-year from $74.5 million in Q1 2024 [28] - The net loss from continuing operations for Q1 2025 was $16.8 million, or $0.16 per share, compared to a net loss of $49 million, or $0.49 per share, in Q1 2024 [28] Business Line Data and Key Metrics Changes - The company is focused on advancing FG3246 and FG3180 in metastatic castration-resistant prostate cancer (mCRPC) [6] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a Type C meeting request filed with the FDA [8][23] Market Data and Key Metrics Changes - There are approximately 290,000 men diagnosed with prostate cancer annually in the U.S., with 65,000 being drug-treatable patients in the mCRPC stage [9] - The total addressable market for FG3246 in mCRPC is estimated to exceed $5 billion in annual sales [10] Company Strategy and Development Direction - The company is divesting FibroGen China to AstraZeneca, with total consideration expected to increase to approximately $185 million, extending the cash runway into the second half of 2027 [5][26] - The strategic focus is on U.S. pipeline opportunities, particularly FG3246 and FG3180, and advancing clinical trials [4][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the refined focus and multiple near-term catalysts across clinical programs to create shareholder value [9] - The company anticipates important feedback from the FDA regarding roxadustat and plans to initiate the Phase II monotherapy study for FG3246 and FG3180 in mCRPC [31] Other Important Information - The company recorded cash flow positive results in Q1 2025, generating $7.3 million in cash flow on a consolidated basis [29] - The IND for FG3180 was cleared, allowing it to be used alongside FG3246 in upcoming trials [7][12] Q&A Session Summary Question: Regarding clinical development on FG3246 and market dynamics after Pluvicto approval - Management confirmed that Pluvicto experienced patients will be allowed in the Phase II monotherapy trial to mitigate enrollment challenges [38][39] Question: Comments on recent FDA communications regarding roxadustat - Management reported favorable interactions with the FDA, including timely responses to IND filings and Type C meeting requests [40][42] Question: Feasibility studies in colorectal cancer due to cash infusion from AstraZeneca - Management indicated that while colorectal cancer is a potential opportunity, the immediate focus is on starting the Phase II monotherapy trial [44][45]